Cognetivity Neurosciences presents at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2021
November 9th, 2021
New results presented at leading conference on Alzheimer’s therapeutic trials provide key evidence supporting use of Cognetivity’s platform to streamline delivery of breakthrough disease-modifying drugs to appropriate patients
VANCOUVER, BC, Nov. 9, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) has presented significant new results demonstrating the capabilities of its Integrated Cognitive Assessment (ICA) platform at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference. Taking place in Boston on 9-12 November, CTAD is the largest meeting in the world dedicated to Alzheimer’s therapeutic trials and has the principal objective of accelerating the development of effective treatments for the disease.
This year, Cognetivity gave a presentation on the ‘Association Between a Computerized, Self-Administered Cognitive Assessment and Fluid Biomarkers of Neurodegeneration’ as part of a session on ‘Cognitive Assessment and Clinical Trials’, which is available throughout the conference. The results demonstrated significant correlations between Cognetivity’s ICA and serum levels of both amyloid β (Aβ) and p-tau in patients with mild cognitive impairment (MCI) and mild Alzheimer’s Disease (AD). Furthermore, it was shown that a new predictive algorithm – involving the input of ICA results, demographic information and APOE4 status (the most prevalent genetic risk factor of AD) – enabled an accurate estimation of Aβ and p-tau in these patients.
Aβ and tau are the key fluid biomarkers of AD and play a vital role in informing its diagnosis and clinical management. However, assessing patients’ Aβ and tau levels requires positron emission tomography (PET) or cerebrospinal fluid (CSF) sampling. These methods are time-consuming, expensive and invasive, and lack scalability, making them highly unsuitable for large-scale use.
At the same time, disease-modifying therapies for AD that target such biomarkers are finally becoming available. Biogen’s Aduhelm received FDA approval earlier this year, with other, similar drugs by Biogen, Eli Lilly and Roche in the late-stage pipeline. Therapies of this kind are effective only on specific underlying pathologies like Aβ or tau and only when used in the early stages of the disease. With 88 million Americans aged 55 and older estimated to be eligible for initial screening for a drug such as Aduhelm, there is a clear need for an easily-accessible, scalable and cost-effective tool to streamline the process of identifying individuals eligible for specific treatments.
Cognetivity’s new results are significant because they mark the first time that a short, visual test such as the ICA has demonstrated predictive ability for such biomarkers. Consequently, they suggest that the ICA is capable of playing a major role in streamlining the rollout of breakthrough disease-modifying drugs for Alzheimer’s.
Commenting on the announcement, Dr Seyed Khaligh-Razavi, Cognetivity’s Chief Scientific Officer, said: “We’re thrilled to have expanded our evidence base and shared further data demonstrating close association between the ICA outcome and the brain’s underlying biological changes in early stages of the disease. In this particular case, the association between the ICA and two key hallmarks of the disease (amyloid beta and p-tau).”
“Investigating such underlying biological changes is typically expensive, invasive and not scalable across a large population,” he continued. “The ICA, however, is quick, simple to administer and highly scalable – a practical solution to the significant and urgent problem of timely dementia diagnosis. Our latest results suggest that the ICA is ready-made for the urgent task of screening large populations and identifying people with higher risk at an early stage who should be referred for further clinical investigation, and thus able to receive treatment early when it is at its most effective.”
About Clinical Trials on Alzheimer’s Disease conference (CTAD)
The Clinical Trials on Alzheimer’s Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease. https://www.ctad-alzheimer.com/
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.
For more information, please visit: www.cognetivity.com or contact: firstname.lastname@example.org
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Cognetivity Neurosciences Ltd
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.